Allegro DVT Supports AV2 Standard Ecosystem with the Launch of Comprehensive Compliance Test Tools

25.9.2025 14:30:00 CEST | Business Wire | Press Release

AllegroDVT, a leading provider of Digital Video Technology Solutions, today announced the release of a complete range of Solutions to accelerate the adoption of the next-generation AV2 codec from the Alliance for Open Media (AOMedia).

The AV2 Codec, set for 2025 year-end release as announced by AOMedia on September 15th, represents a major technological leap in video compression performance. It will notably provide enhanced support for AR/VR applications, better handling of screen content and many other improvements for superior media experiences.

AV2 products announced by AllegroDVT include:

Sirius AV2 Compliance Test Suite – A comprehensive Decoder Verification Solution designed to ease ultimate AV2 conformance based on the publicly available AVM source code. Sirius AV2 Test Suite enables a robust validation of Hardware and Software based AV2 Decoders by providing test cases covering all corner cases, equations, and branch conditions. A full coverage report is also included to give developers complete confidence in their AV2 decoder implementation to meet the highest compliance standards required for market readiness
Astralis AV2 VQ Analyzer – A powerful analysis and debugging tool that provides deep insights into AV2 bitstreams. It helps developers optimize efficiency, accelerates debugging, to deliver higher quality and conformant Video Encoder & Decoders in shorter time-to-market
Pulsar AV2 Decoder Semiconductor IP – Ready-to-integrate Semiconductor IP that brings best-in-class AV2 decoding performance to SoCs powering next generation Consumer devices and streaming platforms while enabling energy-efficient, high-quality playback. Pulsar AV2 Decoder IP will be available shortly after the AV2 specification release

"By combining compliance bitstreams, advanced analysis tools, and semiconductor IPs for the upcoming AV2 codec, AllegroDVT is uniquely positioned to help the video industry foster adoption of AV2 by accelerating the release of AV2 products" said Nouar Hamze, CEO of AllegroDVT. “With over 22 years’ experience, in providing Video Compliance Solutions and successful track record of delivering high quality AV1, VP9, VVC, HEVC, AVC and LCEVC solutions, AllegroDVT shows once again its commitment to supporting open video standards and providing tools and technologies necessary for seamless industry adoption.”

About Allegro DVT
AllegroDVT, a worldwide company headquartered in Grenoble/France, is a leading provider of digital video technology solutions including video compliance tools and semiconductor video IPs. With the acquisition of Vicuesoft, AllegroDVT expanded its video compliance tools portfolio adding the industry leading VQ Analyzer software.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250925020294/en/

Contacts

Press: marcom@allegrodvt.com / +33-04-76-42-66-85

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom